We are steadfast in our commitment to precision research, striving to deliver differentiated and highly effective GPCR-targeting cancer immunotherapies that offer maximum benefit to patients.
Our approach is rooted in a unique understanding of the role of GPCRs in modulating the immune system, the tumor biology, the tumor microenvironment and the immunosuppressive strategies that affect the response to treatment. This profound knowledge is crucial in ensuring optimal clinical development to effectively fight cancer.
We do not settle for one-size-fits-all solutions. Our priority is to identify the right tumor type, the right patient sub-populations and the right combination treatments. We meticulously position each of our immunotherapies to enhance the efficacy of cancer treatment. This precision in positioning is what sets us apart.
A2aR/A2bR antagonist
EP4R antagonist (DT-9081)
Anti-CCR8 antibody
Undisclosed GPCR targets
To pave the way for improved immunotherapies, we focus on the development of a robust and clinically relevant biomarker strategy at the early stages of the drug development process to guide our clinical strategy.
We leverage our proprietary cross-validation drug discovery and development platform to identify leading cancer-focused GPCR targets. Our goal is to reverse GPCR-mediated immunosuppression in immuno-oncology. This in-depth expertise, enriched with valuable biomarkers and careful patient selection, allows us to bring differentiated cancer immunotherapies to the clinic and improve patient outcomes.
| Discovery | Candidate | Preclinical | Phase I | Partner | |
|---|---|---|---|---|---|
| EP4 receptor antagonist (DT-9081) + | Phase I | ||||
| A2aR/A2bR antagonist (M1069) + |
Phase I
|
||||
| Anti-CCR8 depleting antibody (DT-7012) + | Preclinical | ||||
| PAR2 antagonist (DT-9045) + | Preclinical | ||||
| Undisclosed GPCR targets + | Discovery | ||||
